Speciality Medicines IPO
Closed SMEAlready have an account? Apply now
Speciality Medicines IPO details
Schedule of Speciality Medicines
| Issue open date | 20 Mar 2026 |
| Issue close date | 24 Mar 2026 |
| UPI mandate deadline | 24 Mar 2026 (5 PM) |
| Allotment finalization | 25 Mar 2026 |
| Refund initiation | 27 Mar 2026 |
| Share credit | 27 Mar 2026 |
| Listing date | 30 Mar 2026 |
| Mandate end date | 09 Apr 2026 |
| Lock-in end date for anchor investors (50%) | 24 Apr 2026 |
| Lock-in end date for anchor investors (remaining) | 23 Jun 2026 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Speciality Medicines
Speciality Medicines Limited sells medicines used to treat serious and long-term health conditions. These include diseases like cancer, immune-related disorders, neurological conditions, and rare illnesses. The company offers a wide range of medicines in different forms such as tablets, capsules, syrups, injections, and inhalers.It runs its business in two main ways. First, it gets medicines manufactured through third-party manufacturers and supplies them to customers, including in international markets. Second, it sources medicines from manufacturers and markets and distributes them to buyers. The company earns its revenue mainly by selling these pharmaceutical products. Overall, its focus is on providing specialised medicines that are used for complex treatments across different therapeutic areas.
Financials of Speciality Medicines
Issue size
| Funds Raised in the IPO | Amount |
| Total issue size | 29.14 |
| Fresh Issue – Proceeds go to the company | 29.14 |
Utilisation of proceeds
| Purpose | INR crores (%) |
| R&D Center | 12.67 (43.48%) |
| Product Registration (International Markets) | 2.99 (10.26%) |
| Marketing & Brand Promotion | 2 (6.86%) |
| Working Capital Requirements | 8 (27%) |
| General corporate purposes | 3.48 (11.94%) |
Strengths
- Focuses on speciality medicines for complex and chronic diseases.
- Diverse product portfolio across multiple therapeutic areas.
- A wide range of dosage forms enhances product reach.
- Dual business model of manufacturing and distribution.
- Presence in international markets through a distribution network.
Risks
- Dependence on third-party manufacturers for product supply.
- High reliance on a few key customers for revenue.
- Strict quality requirements may lead to order cancellations.
- Ongoing legal proceedings involving a promoter.
- Exposure to supply disruptions and price volatility.
Allotment Status for Speciality Medicines
To check your IPO allotment status:
- Visit the Skyline Financial Services IPO Application Status page.
- Select the company name from the dropdown menu.
- Select and enter one of the following: PAN, Application Number, DP/Client ID, or Account Number/IFSC.
- Click Submit to view your allotment status.
Subscription Figures for Speciality Medicines
According to media reports (Link), Speciality Medicines is seeing no premium in the grey market. Since GMP is an unreliable indicator, IPO subscription data from the exchanges offers a more accurate view of market demand.
Subscription numbers as of 05:00 PM on March 24, 2026:
| Category | Reserved (lakhs) | Applied (lakhs) | Subscription (X times) |
|---|---|---|---|
| Institutional | 0.21 | 20.21 | 96.24x |
| NII | 12.39 | 21.94 | 1.77x |
| Retail | 10.90 | 9.22 | 0.85x |
| Total | 23.50 | 51.37 | 2.19x |